
Iterative Health, a healthcare technology and services company based in Cambridge, Massachusetts, has closed a $77 million Series C financing round to expand its AI-assisted clinical research network. Founded in 2017 by Jonathan Ng, MBBS, the company works with physician practices to run clinical trials more efficiently, connecting drug developers with research sites and the patients those sites can reach.
Getting a new drug to market takes more than good science. It takes a system of research sites that can find patients, enroll them quickly, and keep studies on track. That system is failing in measurable ways. Roughly 80% of clinical trials face delays because of recruitment problems and dropout rates. More than half of research sites enroll one or fewer patients per study, and nearly 90% of US-based trials miss their enrollment targets on time. For patients waiting on new treatments, those delays have real consequences.
The Series C was co-led by Intrepid Growth Partners and GV (Google Ventures). New investors include EDBI, the investment arm of SG Growth Capital backed by Enterprise Singapore and the Economic Development Board, along with a prominent family office. Existing backers Insight Partners and Obvious Ventures also participated.
Most efforts to improve clinical trial performance have targeted isolated problems: better recruitment tools, faster regulatory filings, improved patient tracking. Iterative Health's approach is broader. The company places what it calls site success at the center of trial execution, providing research sites with centralized operations, trained staff, and proprietary AI tools so they can focus on running studies rather than managing logistics.
The results the company reports are worth noting. Compared to industry benchmarks for inflammatory bowel disease trials, Iterative Health's network activates research sites twice as fast, cutting startup timelines by up to three months. Patient enrollment runs at three times the typical rate. Across its global site network, more than two IBD patients are randomized on average every business day.
"Clinical research remains the biggest bottleneck in drug development today. Iterative Health is solving this by using AI to accelerate trial enrollment times and bring new medicines to market faster. Jonathan and his team possess the technical depth and operational expertise needed to tackle clinical trial complexity at scale, and we're excited to support Iterative Health as they expand to new therapeutic areas." — Anthony Philippakis, General Partner of GV.
Iterative Health has built its network primarily around gastroenterology and hepatology, two fields focused on digestive and liver conditions. The new capital will support expansion into cardiology and obesity, areas where the company has recently begun operations, as well as continued geographic growth. The network currently includes more than 100 research sites across North America, Europe, India, and Australia.
The company will also deepen its partnerships with provider organizations. It already works with GI Alliance, OneGI, and US Heart & Vascular, and plans to bring more practices into its network. The aim is to reach community-based clinics where patients already receive care, rather than concentrating research in a small number of specialist centers.
As part of the financing, Ajay Agrawal, Co-Founder and Partner at Intrepid Growth Partners, will join Iterative Health's Board of Directors. Anthony Philippakis, General Partner at GV (Google Ventures), will join as a board observer.
Iterative Health was founded with the goal of making clinical research a standard part of how physicians care for patients, not a separate, complicated undertaking that most practices cannot afford to support. The company employs more than 250 people globally across its Cambridge headquarters and New York City offices.
Its model gives physician practices access to the infrastructure they need to participate in trials: staffing support, regulatory guidance, and operational tools. One of those tools is SKOUT, an AI platform that helps identify eligible patients by analyzing endoscopic images and clinical data. Finding the right patients is often where trials stall, and SKOUT is designed to speed that process up. Sites working with Iterative Health can take on more studies with less operational strain, which is part of why the company's enrollment numbers outperform the industry average.
"Every delay in a clinical trial is a delay for patients whose outcomes depend on faster access to innovation. By keeping our physician partners and their patients at the center of our model, we've built a system that delivers high-performance site execution at scale." — Jonathan Ng, MBBS, Founder and CEO, Iterative Health.
The network now includes partnerships with more than 40 pharmaceutical, biotech, medical device, and contract research organizations.
This Series C is Iterative Health's third known institutional funding round. The company previously raised a Series B in early 2022, in which Insight Partners and Obvious Ventures both participated. Both firms returned for the current round.
Intrepid Growth Partners is a growth equity firm with offices in Toronto and London that focuses on AI-enabled companies. GV is Alphabet's venture capital arm and has invested across life sciences and health technology for over a decade.
"Intrepid invests in growth-stage companies that harness the power of AI to execute profound system redesigns that vastly enhance productivity across their industry. Iterative Health is a perfect example of this thesis, having purpose-built its proprietary technology to power a revolutionary clinical trial network that delivers unparalleled speed and scale to the pharmaceutical sector." — Ajay Agrawal, Co-Founder and Partner, Intrepid Growth Partners.


